Compare · GILD vs TECX
GILD vs TECX
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Tectonic Therapeutic Inc. (TECX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and TECX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $195.13B, about 468.6x TECX ($416.4M).
- TECX has been more active in the news (8 items in the past 4 weeks vs 6 for GILD).
- GILD has more recent analyst coverage (25 ratings vs 12 for TECX).
- Company
- Gilead Sciences Inc.
- Tectonic Therapeutic Inc.
- Price
- -
- -
- Market cap
- $195.13B
- $416.4M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2018
- News (4w)
- 6
- 8
- Recent ratings
- 25
- 12
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 144 filed by Gilead Sciences Inc.
- Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Chairman & CEO O'Day Daniel Patrick sold $2,218,508 worth of shares (15,000 units at $147.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 566,683 units (SEC Form 4)
- SVP, Controllership Burkhart Erin converted options into 2,223 shares and covered exercise/tax liability with 768 shares (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $435,870 worth of shares (3,000 units at $145.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 164,096 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $432,646 worth of shares (3,000 units at $144.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 116,684 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Financial Officer Dickinson Andrew D converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 0.88% to 167,096 units (SEC Form 4)
Latest TECX
- UBS initiated coverage on Tectonic Therapeutic with a new price target
- Chief Financial Officer Lochner Daniel covered exercise/tax liability with 520 shares, decreasing direct ownership by 0.89% to 58,024 units (SEC Form 4) to cover taxes
- Chief Scientific Officer Mcnamara Peter covered exercise/tax liability with 444 shares and sold $12,349 worth of shares (536 units at $23.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 54,305 units (SEC Form 4) to cover withholding tax
- Chief Medical Officer Ruddy Marcella K. covered exercise/tax liability with 525 shares, decreasing direct ownership by 0.78% to 67,157 units (SEC Form 4) to satisfy withholding tax
- Chief Executive Officer Reicin Alise covered exercise/tax liability with 1,545 shares, decreasing direct ownership by 0.50% to 309,078 units (SEC Form 4) (for withholding tax)
- Chief Business Officer Schwabish Marc covered exercise/tax liability with 411 shares, decreasing direct ownership by 0.91% to 44,903 units (SEC Form 4) (withholding obligation)
- SEC Form 8-K filed by Tectonic Therapeutic Inc.
- Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
- SEC Form 4 filed by Chief Executive Officer Reicin Alise
- SEC Form 4 filed by Chief Medical Officer Ruddy Marcella K.